RESUMO
BACKGROUND: Hepatitis is a major public health challenge and a leading cause of death worldwide. We aimed to study the cause-specific incidence and temporal trends of acute viral hepatitis (AVH). METHODS: Data on AVH etiologies were available from the Global Burden of Disease study 2019. Estimated annual percentage change (EAPC) was used to quantify temporal trend in AVH age-standardized incidence rates (ASIRs) by region, sex and aetiology. RESULTS: From 1990 to 2019, the global incidence of AVH increased by 8.02%, from 244 350 063 in 1990 to 263 951 645 in 2019, with an average decreasing ASIR of 0.52% (95% CI -0.58% to -0.45%) annually. The ASIR of AVH due to hepatitis B virus (HBV) decreased, while those of hepatitis A (HAV), hepatitis C (HCV) and hepatitis E (HEV) remained stable, with EAPCs (95% CI) of -1.47 (-1.58 to -1.36), 0 (-0.09 to 0.09), -0.35 (-0.83 to -0.13), and -0.16 (-0.41 to 0.09) respectively. Although the number of new AVH cases increased in the low sociodemographic index (SDI), low-middle SDI regions, the ASIRs decreased in all five SDI regions. Globally, HAV and HBV are the leading causes of acute hepatitis. The EAPC is significantly associated with a baseline ASIR of less than 5500 per 100 000 population (ρ = -0.44), and with the 2019 human development index (HDI) (ρ = 0.16) for AVH. CONCLUSIONS: Although the ASIR of AVH showed a generally decreasing trend, the burden of AVH remains a major public health challenge globally. The findings may be helpful for policymakers in establishing appropriate policies to reduce the viral hepatitis burden.
Assuntos
Hepatite A , Hepatite C , Hepatite E , Humanos , Incidência , Hepatite C/epidemiologia , Hepatite C/complicações , Hepatite E/complicações , Hepacivirus , Hepatite A/epidemiologia , Hepatite A/complicações , Vírus da Hepatite B , Doença Aguda , Carga Global da Doença , Saúde GlobalRESUMO
BACKGROUND: Hepatitis A virus (HAV) infection is a leading cause of viral hepatitis in children, yet the HAV vaccine is not included in the national immunization program (NIP) in Mexico. This study addresses an identified evidence gap of the burden of hepatitis A disease, complications, and associated costs in Mexico by analyzing surveillance and healthcare data. Data review included disease morbidity (incidence and hospitalization), mortality, and healthcare resource utilization costs. METHODS: In this observational, retrospective database study, we conducted a systematic screening, extraction, and analysis of outcome data from the national surveillance system in Mexico from January 2000 to December 2019. RESULTS: During the analysis period (2000-2019), the average incidence rate/year of HAV cases was 14.7 (5.4-21.5) per 100,000 inhabitants. Children 1-9 years of age (YoA) had the highest average incidence rate/year with 47.8 (14.7-74.5). The average hospitalization rate/year due to HAV infection was 5.8% (2.9-9.6%). Although the highest burden of HAV continued to be in children (1-9 YoA), an increase in incidence and hospitalizations (with complications) in older age groups (≥ 10-64 YoA) was observed. The annual average fatality rate was estimated to be 0.44% (0.26-0.83%) of which 28.8% of deaths were concentrated in adults ≥ 65 YoA. The total direct costs of medical attention due to HAV and related complications were estimated at $382 million Mexican pesos. CONCLUSION: The overall results suggest an uptrend in HAV infections in adolescents/adults compared to children in Mexico. Therefore, as the overall incidence risk of HAV infection decreases, the mean age of infection increases. This consequently increases the risk of severity and complications in older age groups, thus increasing the demand for healthcare resources. Our findings provide evidence for including the inactivated HAV vaccine in the Mexican NIP.
Assuntos
Vírus da Hepatite A , Hepatite A , Adolescente , Adulto , Idoso , Criança , Efeitos Psicossociais da Doença , Hepatite A/complicações , Hepatite A/epidemiologia , Vacinas contra Hepatite A , Humanos , México/epidemiologia , Estudos RetrospectivosRESUMO
Baseline adherence to cirrhotic quality improvement measures was assessed and a system to improve adherence with provider performance feedback was developed, with impact of feedback measured over time. A 6-year retrospective database was created of cirrhotic patients seen between 2006 and 2012, and reviewed for hepatitis A and B serologies, hepatocellular carcinoma (HCC) screening, variceal screening, and vaccinations. Cumulative performance feedback was distributed to providers. In all, 265 charts were reviewed retrospectively. Charts were reviewed prospectively at 30 days, 60 days, 6 months, and 12 months. Variceal screening, alpha-fetoprotein, HCC imaging, Pneumovax, lifetime influenza vaccination, hepatitis B vaccination, and hepatitis A serology compliance improved from baseline until 6 months. Hepatitis A vaccination declined at 60 days, but improved from baseline at 6 months. Hepatitis B serology improved from baseline over 12 months. Results were compared graphically. Periodic "cumulative provider performance feedback" is a simple and effective method to improve and maintain adherence to quality measures for cirrhosis.
Assuntos
Retroalimentação , Fidelidade a Diretrizes/organização & administração , Cirrose Hepática/terapia , Guias de Prática Clínica como Assunto , Melhoria de Qualidade/organização & administração , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/etiologia , Detecção Precoce de Câncer/métodos , Varizes Esofágicas e Gástricas/diagnóstico , Varizes Esofágicas e Gástricas/etiologia , Fidelidade a Diretrizes/normas , Hepatite A/complicações , Hepatite A/prevenção & controle , Vacinas contra Hepatite A/administração & dosagem , Hepatite B/complicações , Hepatite B/prevenção & controle , Vacinas contra Hepatite B/administração & dosagem , Humanos , Cirrose Hepática/complicações , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/etiologia , Indicadores de Qualidade em Assistência à Saúde/organização & administração , Indicadores de Qualidade em Assistência à Saúde/estatística & dados numéricos , Estudos Retrospectivos , Estados Unidos , United States Department of Veterans Affairs , alfa-Fetoproteínas/análiseRESUMO
BACKGROUND AND AIM: Hepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with hepatitis C virus (HCV) infection. The aim of this study was to investigate the presence of serological and molecular HAV markers in a population of HCV-infected patients in order to determine a cost-effective strategy to vaccinate against HAV. METHODS: The presence of total and immunoglobulin (Ig)M anti-HAV antibodies was investigated in 399 patients (median age, 50 years; range, 4-81) referred to the Public Health Central Laboratory of Pernambuco State who tested positive for anti-HCV antibodies and HCV RNA. HAV RNA was investigated by reverse transcription-nested polymerase chain reaction in these patients. RESULTS: Three hundred and eighty-four (96%) patients were positive for anti-HAV total and negative for IgM anti-HAV antibodies (immune patients). Three patients had IgM (and total) anti-HAV antibodies, showing an acute infection, and two of them had HAV RNA detected in serum samples. HAV RNA was also found in another patient in the absence of detectable anti-HAV antibodies. By nucleotide sequencing, it was demonstrated that the HAV isolates infecting these patients belonged to subgenotype 1B. CONCLUSION: This study provides valuable new data on anti-HAV prevalence among HCV carriers in Brazil. In the present study, we found a high proportion of patients with anti-HAV positivity, indicating that anti-HAV testing of HCV-infected patients is a cost-effective strategy and should be carried out before vaccination against HAV in these patients, particularly in regions such as our geographical area with high total anti-HAV prevalence.
Assuntos
Vacinas contra Hepatite A , Hepatite A/prevenção & controle , Hepatite C Crônica/tratamento farmacológico , Seleção de Pacientes , Vacinação/economia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil , Criança , Pré-Escolar , Análise Custo-Benefício , Feminino , Genótipo , Hepacivirus/genética , Hepacivirus/imunologia , Hepatite A/complicações , Hepatite A/diagnóstico , Hepatite A/economia , Anticorpos Anti-Hepatite A/sangue , Vacinas contra Hepatite A/economia , Vírus da Hepatite A/genética , Vírus da Hepatite A/imunologia , Anticorpos Anti-Hepatite C/sangue , Hepatite C Crônica/complicações , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/economia , Humanos , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Estudos Soroepidemiológicos , Carga Viral , Adulto JovemRESUMO
Hepatitis A can be a serious disease and represents a substantial health and economic burden. In recent years, a decline in the number of cases of hepatitis A has been observed, which has been attributed in part to the implementation of vaccination policies in states with high disease incidence. In May 2006, the Advisory Committee on Immunization Practices published updated recommendations to include routine hepatitis A vaccination for all children beginning at 12 to 23 months of age. In this review, information on hepatitis A disease burden is presented with a discussion on the new recommendations and implementation of hepatitis A vaccination.
Assuntos
Efeitos Psicossociais da Doença , Hepatite A/epidemiologia , Hepatite A/prevenção & controle , Vacinação , Idoso , Criança , Pré-Escolar , Aprovação de Drogas , Diretrizes para o Planejamento em Saúde , Política de Saúde , Hepatite A/complicações , Hepatite A/transmissão , Vacinas contra Hepatite A/provisão & distribuição , Humanos , Programas de Imunização/organização & administração , Esquemas de Imunização , Incidência , Lactente , Vacinação em Massa/organização & administração , Morbidade , Vigilância da População , Saúde Pública , Fatores de Risco , Índice de Gravidade de Doença , Fatores Socioeconômicos , Estados Unidos/epidemiologia , United States Food and Drug Administration , Vacinação/métodos , Vacinação/estatística & dados numéricosRESUMO
The aim of the study was to determine the prevalence of anti-hepatitis A virus (anti-HAV) antibodies among 172 children with chronic liver disease, and to calculate the cost-effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years.
Assuntos
Hepatite A/diagnóstico , Hepatite A/prevenção & controle , Hepatopatias/virologia , Programas de Rastreamento/economia , Vacinação/economia , Distribuição por Idade , Fatores Etários , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Doença Crônica , Análise Custo-Benefício , Egito/epidemiologia , Diretrizes para o Planejamento em Saúde , Hepatite A/complicações , Hepatite A/epidemiologia , Anticorpos Anti-Hepatite A/sangue , Humanos , Programas de Imunização , Programas de Rastreamento/métodos , Vigilância da População , Avaliação de Programas e Projetos de Saúde , Estudos Soroepidemiológicos , Vacinação/métodosRESUMO
BACKGROUND: HCV infection with concurrent or superinfection with HAV or HBV has the potential to worsen the liver status of HCV-infected individuals. This study evaluates if patients' race or gender influenced whether HAV or HBV serologic status was determined for the purpose of providing immunization. METHODS: Medical records of consecutive African-American and white patients referred for management of HCV were evaluated to determine whether the referring physicians had obtained HAV and HBV serology. RESULTS: Race and gender analysis revealed a statistically significant difference (P < 0.0001) in HAV testing of African-American and white patients, a statistically significant difference in HAV (P < 0.0001) and HBV (P < 0.0001) testing of African-American and white men, and a statistically significant difference (P = 0.0026) in HBV testing of African-American and white women. CONCLUSION: HCV-infected individuals were inconsistently tested for HAV and HBV. Patients' race, but not gender, had a significant impact upon whether HCV-infected individuals were tested for HAV and HBV.
Assuntos
Negro ou Afro-Americano , Hepatite A/diagnóstico , Hepatite B/diagnóstico , Hepatite C Crônica/etnologia , Testes Sorológicos , População Branca , Centros Médicos Acadêmicos , Feminino , Hepatite A/complicações , Hepatite A/etnologia , Hepatite B/complicações , Hepatite B/etnologia , Hepatite C Crônica/complicações , Humanos , Masculino , Auditoria Médica , Encaminhamento e Consulta , Estudos Retrospectivos , Fatores SexuaisRESUMO
Since 1995, the New York State (NYS) Adult Hepatitis Vaccination Program has promoted adult hepatitis B vaccination for those receiving sexually transmitted disease (STD) clinic services. An average of 6,333 doses was administered annually from 1995 to 1999. By 2000, only 15 of 57 county STD programs in NYS outside of New York City participated. From 2000 to 2005, efforts to enroll county health departments and others included outreach, provision of hepatitis A and B vaccine, materials and training, and new collaborations. All 57 counties now participate. From 2000 to 2005, the number of settings offering hepatitis vaccination increased from 57 to 119. Sites include STD clinics; jails; migrant, Indian health, and college health centers; and methadone clinics. More than 125,000 doses of hepatitis A and B vaccine were administered from 1995 through 2005, with annual increases up to a high of 21,025 doses in 2005. Intensive promotion expanded hepatitis vaccination to all county STD clinics and other settings where high-risk adults can be vaccinated.
Assuntos
Instituições de Assistência Ambulatorial/organização & administração , Hepatite A/prevenção & controle , Hepatite B/prevenção & controle , Programas de Imunização/organização & administração , Infecções Sexualmente Transmissíveis/complicações , Instituições de Assistência Ambulatorial/economia , Hepatite A/complicações , Vacinas contra Hepatite A/administração & dosagem , Hepatite B/complicações , Vacinas contra Hepatite B/administração & dosagem , Humanos , Programas de Imunização/economia , New York/epidemiologia , Prática de Saúde Pública , Fatores de Risco , Vacinas Combinadas/administração & dosagemRESUMO
The Healthy Liver Program, established at the Minneapolis Veterans Affairs Medical Center Substance Use Disorder Clinic, provides screening for exposure to hepatitis infections, a group education class, and an individual nursing appointment to review screening results, give vaccinations for hepatitis A and hepatitis B, and make referrals to the hepatitis clinic as appropriate. A patient chart audit was completed 11 months after the establishment of the Healthy Liver Program. The attendance rate for the educational group and individual feedback sessions was 66.9%, with 94.1% of attendees accepting recommended hepatitis A and/or hepatitis B vaccinations. All patients with chronic hepatitis C who attended the Healthy Liver Program received a referral for evaluation in the hepatitis clinic, as compared with only 50% of patients with chronic hepatitis C who were identified before the establishment of the program. The importance of providing comprehensive educational sessions and recommendations for how patients with substance use disorders can access hepatitis screening, vaccination, and treatment resources are stressed.
Assuntos
Hepatite A/prevenção & controle , Hepatite B/prevenção & controle , Hepatite C/prevenção & controle , Serviços Preventivos de Saúde/organização & administração , Centros de Tratamento de Abuso de Substâncias/organização & administração , Veteranos , Feminino , Seguimentos , Hepatite A/complicações , Hepatite B/complicações , Hepatite C/complicações , Hospitais de Veteranos , Humanos , Programas de Imunização/organização & administração , Masculino , Programas de Rastreamento/organização & administração , Auditoria Médica , Pessoa de Meia-Idade , Minnesota , Educação de Pacientes como Assunto/organização & administração , Projetos Piloto , Serviços Preventivos de Saúde/economia , Serviços Preventivos de Saúde/estatística & dados numéricos , Desenvolvimento de Programas , Avaliação de Programas e Projetos de Saúde , Encaminhamento e Consulta , Transtornos Relacionados ao Uso de Substâncias/terapia , Transtornos Relacionados ao Uso de Substâncias/virologia , Estados Unidos , United States Department of Veterans AffairsRESUMO
The importance of vaccination to protect against hepatitis A virus (HAV) and hepatitis B virus (HBV) infections in patients with chronic liver disease has been established. However, in this population, a number of obstacles can interfere with appropriate and timely hepatitis immunization. The costs of hepatitis A and B vaccine series are out of reach for many uninsured patients. Many private and government-sponsored insurance programs do not routinely cover these vaccinations for patients with chronic liver disease. Varying recommendations by government and national organizations, such as the Centers for Disease Control and Prevention (CDC) and the American Association for the Study of Liver Diseases (AASLD), may lead to uncertainty and inconsistent vaccination practices. Because of the need for multiple office visits for prescreening assessment and vaccine administration, patient adherence can be an issue as well. Improved coverage of vaccines by government and third-party health plans is needed, as are uniform guidelines regarding the vaccination of patients with chronic liver disease. Providers should counsel such patients about the serious health risks incurred by infection with HAV or HBV and encourage vaccination in these patients. A combination of interventions can be used to facilitate timely and appropriate vaccination against hepatitis and to improve the affordability of vaccination for patients with chronic liver disease.
Assuntos
Hepatopatias/complicações , Vacinação/métodos , Doença Crônica , Análise Custo-Benefício , Hepatite A/complicações , Hepatite A/prevenção & controle , Hepatite B/complicações , Hepatite B/prevenção & controle , Humanos , Imunização , Seguro Saúde/economia , Hepatopatias/economia , Vacinação/economiaRESUMO
La hepatitis A (HA) es una de las enfermedades inmunoprevenibles más frecuente, constituye actualmente en nuestro país un grave problema de la Salud Pública, por su alta incidencia 40/100.000 habitantes según informe del SINAVE 2002. La complicación más severa es el fallo Hepático fulminante (FHF), emergencia médica que se presenta en el 1/1000 de los pacientes sintomáticos infectados por virus de hepatitis A (VHA). Las tasas de morbimortalidad del FHF continúan siendo altas, lo que genera importantes costos. Nuestro objetivo fue analizar características, evolución y costos de la población internada por FHF secundario a VHA con indicación de trasplante hepático (TXH) en el Hospital de Pediatría Juan P. Garrahan, en el período comprendido entre noviembre de 1992 a junio de 2003. Se analizó: Lugar de procedencia, edad, días de internación en cuidados intermedios (CIM) y/o intensivos (UCI) y evolución. Los costos se obtuvieron del Departamento de Costos del hospital. Para evaluar el tiempo perdido por muerte prematura, utilizamos el cálculo de los años de vida potencial perdidos. Durante el período de estudio se realizaron 308 trasplantes hepáticos. Fueron asistidos por Falla Hepática Fulminante 145 pacientes (p) de ellos el 58 por ciento (p:84) fueron Hepatitis por Virus de Hepatitis A. La edad media de los niños fue de 4.6 años (1a-11a). Los datos de la evolución fueron: el 20 por ciento (n:17) fallecieron en lista de espera de emergencia, el 11 por ciento (n:9). la función hepática se recuperó antes que el injerto apareciera, el 69% (n:58) fueron trasplantados. El TXH se realizó con donante cadavérico en el 90% (n:52) de los casos, se utilizó donante vivo relacionado en el 10 por ciento (n:6). Requirieron retrasplante el (19 por ciento) (n: 11). La mortalidad del FHF por VHA fue del 38 por ciento (n:32). La mortalidad por trasplante hepático fue del 26 por ciento (n:15). Los años perdidos por muerte prematura fueron 2.275 años.
Assuntos
Pré-Escolar , Criança , Custos de Cuidados de Saúde , Evolução Clínica , Falência Hepática Aguda , Hepatite A/complicações , Transplante de Fígado , Epidemiologia Descritiva , Estudos Longitudinais , Estudos RetrospectivosAssuntos
Vacinas contra Hepatite A/economia , Hepatite A/economia , Hepatite A/prevenção & controle , Hepatite C Crônica/complicações , Análise Custo-Benefício , Hepatite A/complicações , Hepatite A/epidemiologia , Vacinas contra Hepatite A/administração & dosagem , Humanos , Anos de Vida Ajustados por Qualidade de Vida , Estados Unidos/epidemiologiaAssuntos
Hepatite Viral Humana/complicações , Hepatopatias/etiologia , Neoplasias Hepáticas/virologia , Pesquisa , Criança , Hepatite A/complicações , Hepatite A/terapia , Hepatite A/virologia , Hepatite B/complicações , Hepatite B/terapia , Hepatite B/virologia , Hepatite C/complicações , Hepatite C/terapia , Hepatite C/virologia , Hepatite Viral Humana/prevenção & controle , Hepatite Viral Humana/terapia , Hepatite Viral Humana/virologia , Humanos , Hepatopatias/virologia , Pesquisa/economiaRESUMO
OBJECTIVES: Although hepatitis A vaccination is recommended for persons with chronic liver disease, the cost-effectiveness of vaccinating patients with chronic hepatitis C virus has not been extensively studied. We evaluated its costs and benefits. METHODS: A Markov model was used to assess cost-effectiveness from the health system and societal perspectives. Costs of hepatitis A screening and vaccination were compared with savings from reduced hepatitis A treatment and work loss to determine net costs of a "screen and vaccinate" strategy. Net costs were compared with longevity gains to assess cost-effectiveness. RESULTS: Based on hypothetical cohorts of 100,000 patients, vaccination would reduce the number of hepatitis A cases 63-72%, depending on patient age. Screening and vaccination costs of $5.2 million would be partially offset by $1.5-$2.8 million reductions in hepatitis A treatment costs and $0.2-$1.0 million reductions in work loss costs. From the health system perspective, vaccination would cost $22,256, $50,391, and $102,064 per life-year saved for patients vaccinated at ages 30, 45, and 60 yr, respectively. Cost-effectiveness ratios improve when work loss prevention is considered. Results are most sensitive to hepatitis A infection and hospitalization rates, and the rate used to discount future benefits to their present values. CONCLUSIONS: Hepatitis A vaccination of chronic hepatitis C patients would substantially reduce morbidity and mortality in all age groups examined. Consistent with other medical interventions for chronic hepatitis C patients, cost-effectiveness is most favorable for younger patients.
Assuntos
Custos de Cuidados de Saúde , Vacinas contra Hepatite A/administração & dosagem , Vacinas contra Hepatite A/economia , Hepatite A/prevenção & controle , Hepatite C Crônica/diagnóstico , Vacinação/economia , Adulto , Idoso , Estudos de Coortes , Análise Custo-Benefício/estatística & dados numéricos , Feminino , Hepatite A/complicações , Hepatite C Crônica/complicações , Humanos , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Estados UnidosRESUMO
Infection with hepatitis A virus (HAV) occasionally leads to acute liver failure and has a higher fatality rate in patients with chronic hepatitis C virus (HCV). Vaccination of patients with HCV against HAV is effective and well tolerated. This study examines the cost-effectiveness of HAV vaccination in North American patients with chronic HCV. A decision analysis model was constructed to compare 3 HAV vaccination strategies in adult patients with chronic HCV over a period of 5 years: (1) vaccinate no patients (treat none); (2) vaccinate only susceptible (anti-HAV negative) patients (selective); or (3) vaccinate all patients without prior testing of immune status (universal). Probabilities and direct costs were estimated from hospital data and the literature. The cost per patient for the 3 vaccination strategies were: treat none, $2.00; selective, $56.00; and universal, $82.00. For every 1,000,000 patients with HCV vaccinated over a 5-year period, the selective strategy prevented 128 symptomatic cases of HAV, 3 liver transplantations, and 3 deaths owing directly to HAV compared with the treat none strategy. In addition, the selective strategy costs an additional $427,000 per patient with HAV prevented, and $23 million per HAV-related death averted, compared with the treat none strategy. The results were most sensitive to the incidence of HAV infection; vaccination increased costs if the annual rate of infection was less than 0.56% (baseline, 0.01%). Vaccination of North American patients with chronic HCV against HAV infection is not a cost-effective therapy.
Assuntos
Análise Custo-Benefício , Hepatite A/prevenção & controle , Hepatite C Crônica/complicações , Vacinas contra Hepatite Viral/economia , Adulto , Hepatite A/complicações , Hepatite A/epidemiologia , Vacinas contra Hepatite A , Hepatite C Crônica/mortalidade , Humanos , Transplante de FígadoRESUMO
The incidence of hepatitis A has declined in the United States for several decades, leading to an increased number of susceptible adolescents and adults. Because clinical severity increases with age, hepatitis A infections in older individuals cause greater morbidity, mortality, and treatment costs. Because the economic burden of hepatitis A has not been well described, we estimated its costs, from the societal perspective, for patients infected at distinct ages. A case-series study described treatment patterns, work loss, and symptom duration. Disease outcomes were estimated by an expert panel. Economic losses were calculated by applying normative data reflecting treatment charges, employee compensation, and the value of housekeeping services. In the case-series study, mean treatment charges were $740 for nonhospitalized patients versus $6,914 for hospitalized patients (P <.001). Symptom duration (67.8 vs. 34.4 days, P <.001) and work loss (33.2 vs. 15.5 days, P <.01) were also greater for those hospitalized. Nationally, we estimate 63,363 symptomatic hepatitis A infections occurred among adolescents and adults during 1997, resulting in 8,403 hospital admissions and 255 deaths. Nearly 2.5 million days of symptomatic illness and 829,000 work-loss days resulted, and 7,466 years of life were lost. Under base-case assumptions, annual hepatitis A costs were estimated at $488.8 million. In sensitivity analyses, this estimate varied from $332.4 to $579.9 million. These costs may be reduced by regionally targeted vaccination of children, as recommended by the Advisory Committee on Immunization Practices, although the cost effectiveness of this policy has not yet been established.
Assuntos
Custos de Cuidados de Saúde , Hepatite A/terapia , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Feminino , Hepatite A/complicações , Hepatite A/diagnóstico , Hepatite A/epidemiologia , Hepatite A/mortalidade , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Estados UnidosAssuntos
Hepatopatias , Ácidos e Sais Biliares/metabolismo , Bilirrubina/sangue , Fatores de Coagulação Sanguínea/análise , Feminino , Encefalopatia Hepática/etiologia , Encefalopatia Hepática/mortalidade , Hepatite A/complicações , Hepatite B/complicações , Humanos , Hepatopatias/complicações , Hepatopatias/etiologia , Hepatopatias/mortalidade , Hepatopatias/patologia , Masculino , Nitrogênio/metabolismo , PrognósticoRESUMO
The reported incidence of viral hepatitis in the Air Force has increased over the past 10 years. The total number of days lost from duty has declined as has the average number of days lost per case. Distribution of USAF reported cases has been roughly equally divided among the three diagnostic categories, in contrast to the total United States reported distribution. Relatively few USAF cases have had a documented history of drug abuse since we began collecting this information, and the proportion of these cases has steadily declined. Finally, these diseases still represent significant economic and operational costs to the Air Force so that prevention and control remain important items of concern to commanders and the medical service.